Product Description: Moxilubant (CGS-25019C;LTB-019) is an orally active BLT1 antagonist which inhibits LTB4 signaling with a potency of 2–4 nM. Moxilubant can be used for cancer research[1].
Formula: C26H37N3O4
References: [1]Bhatt L, et al. Recent advances in clinical development of leukotriene B4 pathway drugs. Semin Immunol. 2017 Oct;33:65-73.